Polypharmacology across 195 putative protein targets

The term Polypharmacology across 195 putative protein targets does not refer to a single molecular target, such as a specific receptor or enzyme, but rather describes a broad pharmacological profile or a specific screening dataset. Polypharmacology is the phenomenon where a single drug molecule interacts with multiple distinct biological targets, a characteristic that is often essential for the efficacy of complex drugs in fields like psychiatry and oncology (Peters, 2013). The specific mention of 195 targets typically refers to a standardized safety pharmacology panel, such as those provided by commercial entities like Cerep or Eurofins, which are used to screen lead compounds for off-target activities (Bowes et al., 2012). These panels include a diverse array of G protein-coupled receptors (GPCRs), ion channels, transporters, and enzymes to predict potential side effects or secondary therapeutic benefits. Because this entry represents a collection of targets rather than a single biological entity, it does not have a unique molecular classification or a single biological function. For biotech analysts, this term signifies a multi-target assessment framework used to evaluate the safety and pleiotropic effects of a drug candidate across the human proteome.

Other names

Multi-target profilingSafety pharmacology panelPromiscuity screeningCerep 195 target panel